THE DIAGNOSTIC VALUE OF CA19.9 IN PREDICTING THE RESECTABILITY OF PANCREATIC CANCER
Ahmed Ibrahim Ali Ibrahim;
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers presenting an increased mortality rate of about 3% of all cancers and about 7% of all cancer death in the United States and Europe.
It is estimated that pancreatic adenocarcinoma has caused 432.242 new deaths in2018. Globally, 458.918 new cases of pancreatic cancer have been reported in 2018 and 355.317 new cases are estimated to occur until 2040.
Due to the late presentations of specific symptoms only10–20% of patients with pancreatic cancer will undergo potentially curative surgery supplemented by adjuvant chemotherapy. Surgery is clearly considered to be the only curative option.
Together with anatomic criteria, different biomarkers have been investigated in order to be considered biological factors defining candidates for surgery. One of them, used for long as potential independent predictor of surgery is the Sialylated Lewis blood group carbohydrate antigen 19.9 (CA19.9).
CA19.9 is detected in low levels in healthy individuals (up to 37 U/ml) and the level is elevated in several types of cancers including pancreatic, and also in benign conditions such as pancreatitis and choledocholithiasis.
Utility of CA19.9 in pancreatic cancer has been explored for screening, diagnostic, prognosis, predictive and also resectability purposes. Preoperative CA19.9 levels are associated with PDAC stage and prognosis, although studies are mostly based on small to moderate-sized patient cohorts.
The study is aimed to evaluate the diagnostic value of CA19.9 in predicting the resectability of pancreatic cancer.
It is estimated that pancreatic adenocarcinoma has caused 432.242 new deaths in2018. Globally, 458.918 new cases of pancreatic cancer have been reported in 2018 and 355.317 new cases are estimated to occur until 2040.
Due to the late presentations of specific symptoms only10–20% of patients with pancreatic cancer will undergo potentially curative surgery supplemented by adjuvant chemotherapy. Surgery is clearly considered to be the only curative option.
Together with anatomic criteria, different biomarkers have been investigated in order to be considered biological factors defining candidates for surgery. One of them, used for long as potential independent predictor of surgery is the Sialylated Lewis blood group carbohydrate antigen 19.9 (CA19.9).
CA19.9 is detected in low levels in healthy individuals (up to 37 U/ml) and the level is elevated in several types of cancers including pancreatic, and also in benign conditions such as pancreatitis and choledocholithiasis.
Utility of CA19.9 in pancreatic cancer has been explored for screening, diagnostic, prognosis, predictive and also resectability purposes. Preoperative CA19.9 levels are associated with PDAC stage and prognosis, although studies are mostly based on small to moderate-sized patient cohorts.
The study is aimed to evaluate the diagnostic value of CA19.9 in predicting the resectability of pancreatic cancer.
Other data
| Title | THE DIAGNOSTIC VALUE OF CA19.9 IN PREDICTING THE RESECTABILITY OF PANCREATIC CANCER | Other Titles | القيمة التشخيصية لدليل الأورام CA19.9 بإمكانية التنبؤ عن سرطان البنكرياس القابل للاستئصال الجراحي | Authors | Ahmed Ibrahim Ali Ibrahim | Issue Date | 2020 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.